Open tender · Germany · Contract notice
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Methylprednisolon, ATC D07AC14 für die Zeit 01.06.2026 - 31.05.2028 (zzgl. Verlängerungsoption 1x12 Monate)
DAK-Gesundheit in Germany is inviting bids for “Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Methylprednisolon, ATC D07AC14 für die Zeit 01.06.2026…”. Bids close on 5 April 2029.
The work
Framework discount agreement for Methylprednisolon (ATC D07AC14) from 01.06.2026 to 31.05.2028 with a 12-month extension option.
- Agreement ends automatically with the entry into force of an exclusive contract.
Key facts
- Contract period
- 01.06.2026 - 31.05.2028 (plus 1x12 month extension option)
- Evaluation
- Selection based on application letter.
What it takes to qualify
Worth a closer look
- § 130a Abs. 8 SGB V enables health insurance funds and pharmaceutical companies to conclude framework discount agreements for medicinal products to be borne by the statutory health insurance funds.
- The procedure is not considered to fall within the scope of cartel procurement law due to the lack of a selection decision and the resulting non-discriminatory access for all pharmaceutical companies.
- The tender is published using the form for open procedures, although it is not one, due to technical reasons as no suitable form for approval procedures exists.
Policy conditions
No reservation, preference or local-content restriction.
Documents to submit
- Angebotsschreibensubmitted via email
- Vertrag mit Namen oder Firmenstempelacknowledging contractual terms and discounts
- Anlage 1 zum Vertragto be filled out and submitted
- Anlage 2 zum VertragExcel file listing medicinal products